VitalHub Announces Licensing Agreement With East Sussex Healthcare NHS Trust
TORONTO, Jan. 16, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") is pleased to announce a licensing agreement...
TORONTO, Jan. 16, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") is pleased to announce a licensing agreement...
AUSTIN, Texas, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Mindbloom, the world’s largest provider of ketamine therapy, announced Monday the launch...
Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA...
BURLINGTON, Mass. and JERUSALEM, Jan. 11, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
TORONTO, Jan. 10, 2023 (GLOBE NEWSWIRE) -- As of June 1, 2023, the Occupational Health and Safety Act (OHSA) will...
BURLINGTON, Mass. and JERUSALEM, Jan. 10, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on...
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a...
HOUSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW), today provided the...
NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on...
SEATTLE, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will participate in the 25th...
TORONTO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) is pleased to announce a five-year licensing...
Program provides healthcare systems and medical providers access to Nue Life’s breakthrough mental health treatment programs and digital support toolsMIAMI,...
Third Quarter Revenues of $38.7 million; Gross Margin of 48%; Adjusted EBITDA of $(1.2) millionRevenues for the Nine-Month Period of...
Company engaged a leading clinical center in Israel and intends to conduct its first- in- human trial in the United...
- This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of...
40,000-square-foot building opening in 2023, will transform women’s healthcare in south Orange County MemorialCare Saddleback Medical Center Celebrates the Forthcoming...
Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes with moderate to severe dementia...
The phase 2b proof-of-concept trial will evaluate the novel compound, RL-007, for pro-cognitive effects in patients with Cognitive Impairment Associated...
CHICAGO and TORONTO, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Wesana Health Holdings Inc. (“Wesana” or the “Company”) (CSE: WESA; OTCQB: WSNAF),...